Trovagene to Attend the 2016 Avondale Partners Healthcare 1-1 Conference
SAN DIEGO, Aug. 9, 2016 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of circulating tumor DNA (ctDNA) molecular diagnostics, is scheduled to attend the 2016 Avondale Partners Healthcare 1-1 Conference on Wednesday, August 10, 2016 at the Boston Harbor Hotel, in Boston, Massachusetts. Bill Welch, Chief Executive Officer of Trovagene, will be attending the conference which consists of one-on-one investor meetings as well as small group meetings. No formal presentations are being made.
About Trovagene, Inc.
Headquartered in San Diego, California, Trovagene is leveraging its proprietary Precision Cancer Monitoring® (PCM) technology for the detection and monitoring of circulating tumor DNA (ctDNA) in urine and blood. The Company's technology detects and quantitates oncogene mutations in cancer patients for improved disease management. Trovagene's PCM technology is designed to provide important clinical information beyond the current standard of care, and is protected by significant intellectual property including multiple issued patents and pending patent applications globally. For more information, please visit http://www.trovagene.com/.
Trovagene Contacts:
Beth Anderson VP, Finance & Administration |
Vicki Kelemen Sr. Director, Marketing Communications | |
858-952-7593 |
858-952-7652 | |
Logo - http://photos.prnewswire.com/prnh/20160520/370471LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/trovagene-to-attend-the-2016-avondale-partners-healthcare-1-1-conference-300311110.html
SOURCE Trovagene, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Northern Dynasty Makes Annual Filings
- ASLAN Pharmaceuticals Announces Receipt of Nasdaq Notice
- RLX Technology Files 2023 Annual Report on Form 20-F
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
Avondale PartnersSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!